Document 0639
 DOCN  M9550639
 TI    Synergistic antimetastatic effects of lentinan and interleukin 2 with
       pre- and post-operative treatments.
 DT    9505
 AU    Hamuro J; Takatsuki F; Suga T; Kikuchi T; Suzuki M; Central Research
       Laboratories, Ajinomoto Co., Inc., Kawasaki.
 SO    Jpn J Cancer Res. 1994 Dec;85(12):1288-97. Unique Identifier : AIDSLINE
       MED/95155164
 AB    The antimetastatic activity of a combination of lentinan and interleukin
       2 (IL-2) was evaluated against spontaneously metastatic
       3-methylcholanthrene-induced DBA/2.MC.CS.T fibrosarcoma. Although
       pre-operative treatment with either IL-2 or lentinan alone exerted
       little effect on the reduction of lung metastasis colony numbers (7.1%
       or 28.4% reduction, respectively), the combination exhibited a
       synergistic effect (85% reduction). Furthermore, 3 of 13 mice given the
       pre-operative combination treatment achieved complete cure, while no
       mice given saline did. Although the post-operative combination treatment
       also reduced the colony number (71% reduction), it caused little
       prolongation of survival and no mouse achieved complete cure.
       Synergistic effects were observed between pre- and post-operative
       treatments with lentinan and IL-2: 8 of 12 mice were completely cured.
       The anti-metastatic activity was abolished in mice treated
       simultaneously with antibodies to CD4 and CD8 antigens, whereas either
       CD4, CD8, or NK1.1 antibody alone was ineffective. Analysis of the
       cellular mechanism involved in the antimetastatic activity revealed the
       involvement of a tumor-associated antigen-specific delayed-type
       hypersensitivity response. These data suggest that the life-prolonging
       effect of the combination of lentinan and IL-2 is mediated by
       antigen-specific T cells and that the combination of pre- and
       post-operative therapy with lentinan and IL-2 may be effective to
       prevent cancer recurrence and metastasis after surgical resection.
 DE    Animal  Antineoplastic Agents, Combined/*THERAPEUTIC USE  CD4-Positive
       T-Lymphocytes/IMMUNOLOGY  CD8-Positive T-Lymphocytes/IMMUNOLOGY  Female
       Fibrosarcoma/CHEMICALLY INDUCED/PATHOLOGY/SECONDARY/THERAPY
       Hypersensitivity, Delayed/IMMUNOLOGY  Immunologic Memory
       Immunotherapy/*METHODS  Interleukin-2/*ADMINISTRATION & DOSAGE  Killer
       Cells, Natural/IMMUNOLOGY  Lentinan/*ADMINISTRATION & DOSAGE  Lung
       Neoplasms/PREVENTION & CONTROL/SECONDARY  Melanoma,
       Experimental/PREVENTION & CONTROL/SECONDARY  Methylcholanthrene  Mice
       Mice, Inbred C57BL  Mice, Inbred DBA  Neoplasm Metastasis/*PREVENTION &
       CONTROL  Postoperative Care  Preoperative Care  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).